HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INNOGEN-B

3.870

-0.150-3.73%

Volume:9.25M

Turnover:35.77M

Market Cap:1.77B

PE:-4.20

High:4.050

Open:4.040

Low:3.775

Close:4.020

52wk High:50.500

52wk Low:3.775

Shares:457.00M

HK Float Shares:420.29M

Volume Ratio:1.06

T/O Rate:2.20%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.921

ROE:-41.16%

ROA:-20.15%

PB:1.61

PE(LYR):-4.20

PS:9.89

Loading ...

Overview Company News Filings

Guangzhou Innogen Says Anvisa Grants PIC/S GMP Certificates for Two Contract Sites for Ecnoglutide Alpha Injection

INNOGEN-B (02591) Depositary Shares Valued at HK$188 Million; Shareholder Deposits 25.29 Million Shares with Citibank

Innogen Pharma Doses First Patient in Phase 1b Trial of Obesity Drug

MT Newswires Live

INNOGEN-B completes first patient dosing in Phase Ib adolescent-obesity trial for Efsubaglutide Alfa

Bulletin Express

Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591): Is Breakeven Near?

Simply Wall St.

Assessing Supply Chain Compliance Risks for a Company with a Single Commercial Product: The INNOGEN-B Patent Infringement Case

INNOGEN-B Shares Surge Over 17% Following NMPA Approval for Adolescent Weight Loss Trial of Esupaglutide α

Innogen Pharmaceutical CEO addresses DIA Global Annual Meeting 2026 China Town Hall

BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug

BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial

Innogen Pharma Gets Clinical Trial Nod for Obesity Drug in China

MT Newswires Live

INNOGEN-B Receives NMPA Clearance for Phase Ib Trial of Esupaglutide Alpha in Adolescent Obesity

Guangzhou Innogen Pharmaceutical Group Co - on 17 June, Receives China Approval to Start Phase Ib Trial for Efsubaglutide Alfa in Adolescent Obesity

THOMSON REUTERS

Innogen Pharmaceutical Sets 29 June 2026 AGM; Seeks to Scrap Supervisory Committee and Launch Share Award Scheme

Bulletin Express

INNOGEN-B AGM Agenda: Share Award Scheme, 20% Issue Mandate, Supervisory Committee Abolition

Bulletin Express

INNOGEN-B Shares Surge Over 9% as Its Proprietary Drug Features at Major Diabetes Conference

INNOGEN-B’s May 2026 Monthly Return Shows Stable Share Structure and Compliance With Public Float Rules

Bulletin Express

INNOGEN-B Shares Surge Over 6% Ahead of Key Clinical Data Presentation at ADA 2026

Movement Alert｜Yinnuo Pharma-B Rises 10.68% in Regular Trading, Share Award Plan and Commercialization Acceleration Drive Gains

INNOGEN-B Proposes Adoption of Share Incentive Scheme

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigermarketb.com/stock/02591/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"INNOGEN-B","latestPrice":3.87,"timestamp":1787818111006,"preClose":4.02,"halted":0,"volume":9245600,"delay":0,"changeRate":-0.03731343283582077,"floatShares":420285370,"shares":457000000,"eps":-0.9214478552615077,"marketStatus":"Closed","change":-0.15,"latestTime":"08-27 16:08:31","open":4.04,"high":4.05,"low":3.775,"amount":35765290,"amplitude":0.068408,"askPrice":3.875,"askSize":24800,"bidPrice":3.87,"bidSize":20800,"shortable":3,"etf":0,"ttmEps":-0.8592851167220622,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787880600000},"marketStatusCode":5,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":4.02,"openAndCloseTimeList":[[1787794200000,1787803200000],[1787806800000,1787817600000]],"volumeRatio":1.063436,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-20.15%","roe":"-41.16%","lyrEps":-0.921448,"volumeRatio":1.063436,"shares":457000000,"dividePrice":0,"high":4.05,"amplitude":0.068408,"preClose":4.02,"low":3.775,"week52Low":3.775,"pbRate":"1.61","psRate":"9.89","week52High":50.5,"institutionHeld":0,"latestPrice":3.87,"committee":-0.087719,"eps":-0.9214478552615077,"divideRate":0,"volume":9245600,"delay":0,"ttmEps":-0.8592851167220622,"open":4.04,"prevYearClose":30.64,"prevWeekClose":4.08,"prevMonthClose":7.26,"prevQuarterClose":7.09,"fiveDayClose":4.21,"twentyDayClose":7.11,"sixtyDayClose":10.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02591","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1775750400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2026-08-26","current":-4.503744,"percent":1,"low":-137.156472,"twenty":-68.822396,"median":-49.689505,"eighty":-11.970611,"high":-4.710919,"avg":-45.226362,"sd":30.098379,"marketCap":1836413782},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743},{"date":"2025-11-21","current":-54.467459,"twenty":-87.179427,"median":-75.823033,"eighty":-60.1184,"marketCap":13229488347},{"date":"2025-11-28","current":-82.342484,"twenty":-85.508442,"median":-76.5387,"eighty":-60.703449,"marketCap":20072642195},{"date":"2025-12-05","current":-82.313405,"twenty":-85.248884,"median":-75.823033,"eighty":-61.326336,"marketCap":20100051356},{"date":"2025-12-12","current":-63.824496,"twenty":-84.462171,"median":-74.404407,"eighty":-61.326336,"marketCap":15614085348},{"date":"2025-12-19","current":-62.072323,"twenty":-83.725798,"median":-74.049705,"eighty":-60.286674,"marketCap":15221220708},{"date":"2025-12-24","current":-59.762449,"twenty":-83.548712,"median":-73.276127,"eighty":-59.816947,"marketCap":14700446650},{"date":"2026-01-02","current":-56.27243,"twenty":-83.409096,"median":-71.366231,"eighty":-59.572219,"marketCap":13896444596},{"date":"2026-01-09","current":-57.1291,"twenty":-82.548826,"median":-69.803372,"eighty":-58.239982,"marketCap":14143127045},{"date":"2026-01-16","current":-56.980838,"twenty":-82.319221,"median":-67.499105,"eighty":-57.682607,"marketCap":14152263432},{"date":"2026-01-23","current":-58.213825,"twenty":-82.096799,"median":-66.291021,"eighty":-57.601428,"marketCap":14444627815},{"date":"2026-01-30","current":-54.613459,"twenty":-81.934522,"median":-64.906051,"eighty":-57.510573,"marketCap":13613216600},{"date":"2026-02-06","current":-49.064319,"twenty":-80.235292,"median":-63.834,"eighty":-57.242442,"marketCap":12261031327},{"date":"2026-02-13","current":-50.165477,"twenty":-79.691019,"median":-62.941647,"eighty":-57.039695,"marketCap":12608214032},{"date":"2026-02-20","current":-50.419859,"twenty":-79.623791,"median":-62.643943,"eighty":-56.891323,"marketCap":12653895967},{"date":"2026-02-27","current":-50.052949,"twenty":-79.470699,"median":-62.017016,"eighty":-56.651056,"marketCap":12699577902},{"date":"2026-03-06","current":-43.88908,"twenty":-79.397543,"median":-60.902753,"eighty":-56.29247,"marketCap":11045891858},{"date":"2026-03-13","current":-39.965904,"twenty":-79.214462,"median":-60.292057,"eighty":-54.71959,"marketCap":10104843999},{"date":"2026-03-20","current":-39.174717,"twenty":-78.964109,"median":-59.813644,"eighty":-50.865048,"marketCap":9867297938},{"date":"2026-03-27","current":-24.701097,"twenty":-78.775514,"median":-59.491697,"eighty":-50.290678,"marketCap":9547524394},{"date":"2026-04-02","current":-24.535908,"twenty":-78.383597,"median":-58.823921,"eighty":-50.052949,"marketCap":9529251620},{"date":"2026-04-10","current":-24.978414,"twenty":-78.348547,"median":-58.584467,"eighty":-49.631191,"marketCap":9775934068},{"date":"2026-04-17","current":-23.474521,"twenty":-78.227102,"median":-58.112982,"eighty":-48.421657,"marketCap":9191205301},{"date":"2026-04-24","current":-19.658213,"twenty":-78.155492,"median":-57.844151,"eighty":-44.116877,"marketCap":7697406030},{"date":"2026-04-30","current":-16.329046,"twenty":-77.825679,"median":-57.660489,"eighty":-41.074266,"marketCap":6395470886},{"date":"2026-05-08","current":-17.822364,"twenty":-77.322024,"median":-57.626503,"eighty":-40.478309,"marketCap":5778764764},{"date":"2026-05-15","current":-17.368107,"twenty":-77.157551,"median":-57.517602,"eighty":-40.012158,"marketCap":5646287153},{"date":"2026-05-22","current":-17.112125,"twenty":-76.782452,"median":-57.446424,"eighty":-25.37304,"marketCap":5550355090},{"date":"2026-05-29","current":-15.607197,"twenty":-76.252433,"median":-57.23775,"eighty":-24.916387,"marketCap":5079831160},{"date":"2026-06-05","current":-14.014909,"twenty":-75.020932,"median":-57.073515,"eighty":-24.414835,"marketCap":4568193490},{"date":"2026-06-12","current":-11.752443,"twenty":-74.621039,"median":-56.924891,"eighty":-23.900197,"marketCap":3828146144},{"date":"2026-06-18","current":-10.549084,"twenty":-74.404407,"median":-56.73827,"eighty":-23.474521,"marketCap":3444417891},{"date":"2026-06-26","current":-9.60263,"twenty":-74.160764,"median":-56.642046,"eighty":-20.865982,"marketCap":3120076153},{"date":"2026-07-03","current":-11.351574,"twenty":-74.088566,"median":-56.533624,"eighty":-19.581214,"marketCap":3691100339},{"date":"2026-07-10","current":-11.238926,"twenty":-74.037218,"median":-56.208644,"eighty":-19.055481,"marketCap":3649986598},{"date":"2026-07-17","current":-10.540302,"twenty":-73.42668,"median":-55.144116,"eighty":-17.753872,"marketCap":3435281504},{"date":"2026-07-24","current":-10.636027,"twenty":-71.947117,"median":-53.621015,"eighty":-17.028947,"marketCap":3467258858},{"date":"2026-07-31","current":-10.1543,"twenty":-71.465685,"median":-51.153424,"eighty":-16.590446,"marketCap":3316508473},{"date":"2026-08-07","current":-10.609247,"twenty":-70.999854,"median":-50.412223,"eighty":-15.817726,"marketCap":3471827052},{"date":"2026-08-14","current":-9.215586,"twenty":-70.625283,"median":-50.222782,"eighty":-14.020929,"marketCap":3019575896},{"date":"2026-08-21","current":-5.675745,"twenty":-69.656366,"median":-50.052949,"eighty":-12.083492,"marketCap":1863822943},{"date":"2026-08-26","current":-4.710919,"twenty":-68.822396,"median":-49.689505,"eighty":-11.970611,"marketCap":1836413782}],"updateTime":1787822847577},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656757753","title":"Guangzhou Innogen Says Anvisa Grants PIC/S GMP Certificates for Two Contract Sites for Ecnoglutide Alpha Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2656757753","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656757753?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:43","pubTimestamp":1785757420,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen says ANVISA grants PIC/S GMP certificates for two contract sites for ecnoglutide alpha injectionGuangzhou Innogen said two third-party contract manufacturing sites for its ecnoglutid","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL6hQ8mJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119793972","title":"INNOGEN-B (02591) Depositary Shares Valued at HK$188 Million; Shareholder Deposits 25.29 Million Shares with Citibank","url":"https://stock-news.laohu8.com/highlight/detail?id=1119793972","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119793972?lang=en_us&edition=fundamental","pubTime":"2026-07-31 08:26","pubTimestamp":1785457575,"startTime":"0","endTime":"0","summary":"Data from the Hong Kong Stock Exchange shows that on July 30, a significant position change occurred in INNOGEN-B (02591), with depositary shares valued at a total of HK$188 million, representing a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU0052756011.USD","LU1668664300.SGD","LU1244550494.USD","LU1244550577.SGD","BK4534","BK1161","LU0203347892.USD","LU2125154778.USD","02591","BK4588","LU0098860793.USD","LU2462157665.USD","LU0648001328.SGD","BK4559","LU1366192091.USD","LU1162221912.USD","LU1267930227.SGD","LU1074936037.SGD","LU1506573853.SGD","LU2125154935.USD","IYF","BK4207","BK4566","LU2417539215.USD","LU2456880835.USD","LU0170899867.USD","FTXO","TFNS","LU0162691827.USD","C","LU0106831901.USD","LU0314106906.USD","LU0477156953.USD","LU1791807156.HKD","LU1244550221.USD","BK4585","LU2360032135.SGD","LU0072461881.USD","LU0320765646.SGD","LU0310800965.SGD","LU2236285917.USD","LU0203345920.USD","LU0980610538.SGD","BK4504","LU0130517989.USD","LU1201861249.SGD","LU0130102774.USD","LU0128525689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655830996","title":"Innogen Pharma Doses First Patient in Phase 1b Trial of Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2655830996","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655830996?lang=en_us&edition=fundamental","pubTime":"2026-07-29 10:50","pubTimestamp":1785293403,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  has enrolled and dosed the first patient in the Phase 1b clinical trial of Efsubaglutide Alfa for the treatment of adolescent obesity, according to a Tuesday Hong Kong bourse filing.The company said that no safety concerns or adverse reactions were observed during the post-dosing observation period.Shares of the pharma company were up more than 2% in Wednesday morning trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168740565","title":"INNOGEN-B completes first patient dosing in Phase Ib adolescent-obesity trial for Efsubaglutide Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1168740565","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168740565?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:46","pubTimestamp":1785242819,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) reported that the first adolescent patient has been enrolled and dosed in the Phase Ib clinical trial of Efsubaglutide Alfa for obesity...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651156964","title":"Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591): Is Breakeven Near?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651156964","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651156964?lang=en_us&edition=fundamental","pubTime":"2026-07-16 11:38","pubTimestamp":1784173082,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd ( HKG:2591 ) is possibly approaching a major achievement in its...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2591/guangzhou-innogen-pharmaceutical-group-shares/news/guangzhou-innogen-pharmaceutical-group-co-ltd-hkg2591-is-bre","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2591/guangzhou-innogen-pharmaceutical-group-shares/news/guangzhou-innogen-pharmaceutical-group-co-ltd-hkg2591-is-bre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101364795","title":"Assessing Supply Chain Compliance Risks for a Company with a Single Commercial Product: The INNOGEN-B Patent Infringement Case","url":"https://stock-news.laohu8.com/highlight/detail?id=1101364795","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101364795?lang=en_us&edition=fundamental","pubTime":"2026-07-10 14:21","pubTimestamp":1783664460,"startTime":"0","endTime":"0","summary":"The Beijing Intellectual Property Court has recently accepted a utility model patent infringement case filed by Suzhou Jiashu Biology against Shanghai Yinno Medicine and Beijing JD Pharmacy. While JD...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123803607","title":"INNOGEN-B Shares Surge Over 17% Following NMPA Approval for Adolescent Weight Loss Trial of Esupaglutide α","url":"https://stock-news.laohu8.com/highlight/detail?id=1123803607","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123803607?lang=en_us&edition=fundamental","pubTime":"2026-06-23 09:58","pubTimestamp":1782179905,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) are currently trading sharply higher, with gains exceeding 17%. At the time of writing, the stock is up 14.03% to HK$8.94, with a trading turnover of HK$45.71 million.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","02591","IND","BK4588","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645040877","title":"Innogen Pharmaceutical CEO addresses DIA Global Annual Meeting 2026 China Town Hall","url":"https://stock-news.laohu8.com/highlight/detail?id=2645040877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645040877?lang=en_us&edition=fundamental","pubTime":"2026-06-22 16:40","pubTimestamp":1782117613,"startTime":"0","endTime":"0","summary":"Innogen joined the DIA Global Annual Meeting 2026 China Town Hall session in Philadelphia.CEO Qinghua Wang outlined efsubaglutide alfa’s China approval for type 2 diabetes, citing ongoing obesity Phase 2 in Australia, diabetes bridging study in Brazil.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL147jTz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044484","title":"BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044484","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645044484?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:36","pubTimestamp":1782113804,"startTime":"0","endTime":"0","summary":"BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug** Shares of Guangzhou Innogen Pharmaceutical Group 2591.HK climb 4.4% to HK$7.87, on course for the biggest one-day pct gain since May 19** Hong Kong-listed pharmaceutical products developer says it has received approval from China's National Medical Products Administration to commence Phase Ib clinical trials for its Efsubaglutide Alfa for the treatment of obesity in adolescents** Company expects to commence clinical trial in July 2026 and plans to enroll about 36 participants for the clinical trial** YTD, stock down 74.6%, Hang Seng Biotech Index .HSBIO donw 15.7%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL1N42U07V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645497610","title":"BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645497610","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645497610?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:48","pubTimestamp":1782110893,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial June 22  - Guangzhou Innogen Pharmaceutical Group Co Ltd 2591.HK:GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO - ON 17 JUNE, RECEIVES CHINA APPROVAL TO START PHASE IB TRIAL FOR EFSUBAGLUTIDE ALFA IN ADOLESCENT OBESITYFurther company coverage: 2591.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645049125","title":"Innogen Pharma Gets Clinical Trial Nod for Obesity Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2645049125","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645049125?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:38","pubTimestamp":1782110339,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  obtained approval to conduct phase Ib clinical trials for Efsubaglutide Alfa from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The drug is being tested for the treatment of obesity in adolescents.The company expects to begin the trial in July and enroll around 36 participants.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183559762","title":"INNOGEN-B Receives NMPA Clearance for Phase Ib Trial of Esupaglutide Alpha in Adolescent Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=1183559762","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183559762?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:49","pubTimestamp":1782103749,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) has announced that it received approval from China's National Medical Products Administration (NMPA) on June 17, 2026, to initiate a Phase Ib clinical trial for its drug candidate,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645704354","title":"Guangzhou Innogen Pharmaceutical Group Co - on 17 June, Receives China Approval to Start Phase Ib Trial for Efsubaglutide Alfa in Adolescent Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2645704354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645704354?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:07","pubTimestamp":1782101278,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185876958","title":"Innogen Pharmaceutical Sets 29 June 2026 AGM; Seeks to Scrap Supervisory Committee and Launch Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1185876958","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185876958?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:05","pubTimestamp":1780661110,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“Innogen Pharmaceutical”), stock name INNOGEN-B, has issued a proxy circular outlining 24 resolutions to be tabled at its annual general meeting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155251925","title":"INNOGEN-B AGM Agenda: Share Award Scheme, 20% Issue Mandate, Supervisory Committee Abolition","url":"https://stock-news.laohu8.com/highlight/detail?id=1155251925","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155251925?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:26","pubTimestamp":1780658769,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) has published a circular for its Annual General Meeting (AGM) scheduled on 29 June 2026 in Shanghai, detailing 17 resolutions for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179509312","title":"INNOGEN-B Shares Surge Over 9% as Its Proprietary Drug Features at Major Diabetes Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1179509312","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179509312?lang=en_us&edition=fundamental","pubTime":"2026-06-05 11:12","pubTimestamp":1780629145,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) surged more than 9% during the trading session. At the time of writing, the stock was up 3.21% to HK$10.28, with a turnover of HK$34.87 million. The catalyst for the move...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VXUS","BK4588","02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134785093","title":"INNOGEN-B’s May 2026 Monthly Return Shows Stable Share Structure and Compliance With Public Float Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=1134785093","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134785093?lang=en_us&edition=fundamental","pubTime":"2026-06-03 17:25","pubTimestamp":1780478754,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B) filed its Monthly Return for the period ended 31 May 2026, confirming that no changes occurred in either authorised or issued share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162227797","title":"INNOGEN-B Shares Surge Over 6% Ahead of Key Clinical Data Presentation at ADA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1162227797","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162227797?lang=en_us&edition=fundamental","pubTime":"2026-06-03 11:08","pubTimestamp":1780456101,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) have risen more than 6%. At the time of writing, the stock is up 5.79% to HK$10.62, with a turnover of HK$90.33 million.The company has announced that it will present data...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1161","VXUS","02591","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116975222","title":"Movement Alert｜Yinnuo Pharma-B Rises 10.68% in Regular Trading, Share Award Plan and Commercialization Acceleration Drive Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1116975222","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116975222?lang=en_us&edition=fundamental","pubTime":"2026-06-03 10:38","pubTimestamp":1780454339,"startTime":"0","endTime":"0","summary":"On June 3, Yinnuo Pharma-B rose 10.68% in regular trading, trading at 11.37 HKD/share, with trading volume of approximately 29.62 million HKD, significantly outperforming the broader Biotechnology...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132169066","title":"INNOGEN-B Proposes Adoption of Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1132169066","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132169066?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:40","pubTimestamp":1780324820,"startTime":"0","endTime":"0","summary":"INNOGEN-B (HKEX: 02591) has announced that its board of directors has proposed the adoption of a share reward plan.In accordance with the provisions of the company's articles of association, a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0251","BK1161","301122","02591"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":100,"code":"91000000","status":"200"}]}}